Ashlei Wooten
Family · San Antonio, TXNPI 1619425709
Payments from drug & device makers
Across 148 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$835
- AbbVie$283
- Lilly USA, LLC$277
- AstraZeneca$229
- Merck$118
- Bayer$90
- plus $716 from 24 others
What the payments were for
- Food & beverage$2,547100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $835 |
| AbbVie | 22 | $283 |
| Lilly USA, LLC | 17 | $277 |
| AstraZeneca | 13 | $229 |
| Merck | 7 | $118 |
| Bayer | 5 | $90 |
| Amarin Pharma, Inc. | 4 | $77 |
| Boehringer Ingelheim | 3 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Amgen(2 entities) | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Johnson & Johnson | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Philips North America LLC | 1 | $24 |
| Pfizer | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Novartis | 1 | $16 |
| Si-bone, Inc. | 1 | $16 |
| Intuity Medical Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
How this compares
$2,547 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $119,576 |
| TrulicityDulaglutide | 23 | $45,211 |
| JanuviaSitagliptin Phosphate | 22 | $34,752 |
| JardianceEmpagliflozin | 23 | $25,103 |
| MounjaroTirzepatide | 20 | $21,323 |
| LinzessLinaclotide | 17 | $18,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $18,040 |
| XareltoRivaroxaban | 11 | $16,405 |
| MyrbetriqMirabegron | 11 | $11,760 |
| FarxigaDapagliflozin Propanediol | 11 | $11,439 |
| Diclofenac Sodium | 37 | $4,315 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,478 |
| Malathion | 11 | $2,364 |
| Lubiprostone | 14 | $2,133 |
| Humalog Mix 75-25Insulin Lispro Protamin/Lispro | 14 | $1,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $835 | $119,57693 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog Mix 75-25 | $277 | $67,85457 claims |
| MerckJanuvia | $118 | $34,75222 claims |
| Boehringer IngelheimJardiance | $58 | $25,10323 claims |
| AbbVieLinzess | $283 | $18,65817 claims |
| Johnson & JohnsonXarelto | $30 | $16,40511 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $11,76011 claims |
| AstraZenecaFarxiga | $229 | $11,43911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.